Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Bank of America Global Healthcare Conference 2026 September 22, 2026 8:20 AM EDT
Company Participants
Matthew Gline – CEO & Director
Conference Call Participants
Richard Wagner – BofA Securities, Research Division
Presentation
Richard Wagner
BofA Securities, Research Division
Good afternoon. Welcome back from lunch. To introduce myself, my name is Richard Wagner. I work with Jason Gerberry on the U.S. large-cap pharma names. I’m based in London. On behalf of my colleagues, Chi Fong and Dina Ramadane, covering analysts for Roivant and Immunovant, respectively, I’m pleased to welcome Matthew Gline, CEO of Roivant for a 40-minute fireside chat.
Matthew Gline
CEO & Director
Thank you, Richard.
Question-and-Answer Session
Richard Wagner
BofA Securities, Research Division
Roivant has achieved several key milestones this year, including positive Phase II readout of your once-daily inhaled sGC mosliciguat in PH-ILD and approval of your TYK2 JAK inhibitor, brepocitinib in dermatomyositis. We still have multiple readouts coming up before year-end. To help level set the discussions, what would be the company’s top priorities in the next 12 months?
Matthew Gline
CEO & Director
Yes, perfect. So look, it’s been a period of a lot of progress for us. It’s been a great 12 months behind. We just, as you mentioned, got brepocitinib, now LISRAYA approved, and we’re making some real progress on the SGC front on the pulmonary hypertension franchise. Look, coming up the next 12 months, very busy 12 months ahead. Obviously, one of the most important things for us is with brepocitinib now in the market, we’re in the early innings of that launch, but we want to go as well as we possibly can have it. And so there’s a lot of work going into making that successful.
We have some major clinical data coming in brepocitinib, including between now
